3Wu HM, Seet B, Yap EP, et al. Does education explain ethnic differences in myopia prevalence? A population -based study of young adult males ill Singapore [J]. Optom Vis Sci, 2001,78(4) : 234-239.
4Kalz J, Tielseh JM, Sommer A. Prevalence and risk factnrs for refractive errors in an aduh inner city population [J]. Invest Ophthahnol Vis Sci, 1997,38(2) : 334-340.
5Chua WH, Balakrishnan V, Chan YH, et al. Atropine for the treatment of childhood myopia[J]. Ophthalrnology,2006,113(12): 2285-2291.
6Tan DT, Lain DS, Chua WIt, et al. One-year multicenter, double-masked, placebo-controlled, parallel safety and efficacy study of 2% pirenzepine ophthahnic gel in chihtren with myopia[J]. Ophthahnology,2005, 112(1):84-91.
7McBrien NA, Moghaddam HO, Reeder AP. Atropine reduees experimental myopia and eye enlargement via a nonaecom- modative mechanism[J]. Invest Ophthahnol Vis Sci, 1993,34(1): 205-215.
8Truong HT, Cottriall Cl,, Gentle A, et al. Pirenzepine affects seleral metabolic changes in myopia through a non -toxic meehanism[J]. Exp Eye Res,2002,74(1) : 103-111.
9Stone RA, Sugimoto R, Gill AS, et al. Effects of nicotinic antagonists on ocular growth and experimenlal myopia[J]. Invest Ophthahnol Vis Sci,2001,42(3):557-565.
10Lind GJ CS, Marzani D, Wallman J. Muscarinic acetylcholine receptor antagonists inhibit chick scleral chondrocytes. Invest Ophthalmol Vis Sci,1998, 39:2217-2231.
